公开(公告)号：AU6201973A

公开(公告)日：1975-05-01

申请号：AU6201973

申请日：1973-10-31

Applicant: KOWA CO

Inventor： OHTANI GENJI ,  SHIMIZU NOBORU ,  OTA TOMIO ,  SAKAI HIDEO ,  NAGAKURA MASAHIKO

IPC: C07D231/56 ,  A61K27/00 ,  C07D49/00

公开(公告)号：DE68913965D1

公开(公告)日：1994-04-21

申请号：DE68913965

申请日：1989-12-25

Applicant: KOWA CO

Inventor： KAWAMURA KIYOSHI ,  OTA TOMIO

IPC: C07D301/28 ,  C07D303/22 ,  C07D405/12 ,  C07D407/12 ,  C07D417/12

公开(公告)号：DE2354610A1

公开(公告)日：1974-05-16

申请号：DE2354610

申请日：1973-10-31

Applicant: KOWA CO

Inventor： OHTANI GENJI ,  NAGAKURA MASAHIKO ,  OTA TOMIO ,  SHIMIZU NOBORU ,  HIGASHIMURAYAMA TOKIO ,  SAKAI HIDEO

IPC: C07D231/56 ,  C07D49/02

公开(公告)号：DE68913965T2

公开(公告)日：1994-08-04

申请号：DE68913965

申请日：1989-12-25

Applicant: KOWA CO

Inventor： KAWAMURA KIYOSHI ,  OTA TOMIO

IPC: C07D301/28 ,  C07D303/22 ,  C07D405/12 ,  C07D407/12 ,  C07D417/12

公开(公告)号：ES2050425T3

公开(公告)日：1994-05-16

申请号：ES90900359

申请日：1989-12-25

Applicant: KOWA CO

Inventor： KAWAMURA KIYOSHI ,  OTA TOMIO

IPC: C07D301/28 ,  C07D303/22 ,  C07D405/12 ,  C07D407/12 ,  C07D417/12

公开(公告)号：AT102931T

公开(公告)日：1994-04-15

申请号：AT90900359

申请日：1989-12-25

Applicant: KOWA CO

Inventor： KAWAMURA KIYOSHI ,  OTA TOMIO

IPC: C07D301/28 ,  C07D303/22 ,  C07D405/12 ,  C07D407/12 ,  C07D417/12

公开(公告)号：EP0638571A4

公开(公告)日：1995-04-12

申请号：EP93911951

申请日：1993-04-28

Applicant: KOWA CO

Inventor： KYOTANI YOSHINORI ,  OGIYA TADAAKI ,  TOMA TSUTOMU ,  KURIHARA YUJI ,  KITAMURA TAKAHIRO ,  YAMAGUCHI TAKASHI ,  ONOGI KAZUHIRO ,  SATO SEICHI ,  SHIGYO HIROMICHI ,  OTA TOMIO ,  KAWADA MITSUO ,  UCHIDA YASUMI

IPC: C07D491/04 ,  C07D491/048 ,  C07D491/056 ,  A61K31/47

CPC classification number: C07D491/04

Abstract: A quinoline derivative represented by general formula (1), a medicinally acceptable salt thereof, and a remedy for cardiac diseases containing the same, wherein ring A represents a furan, dihydrofuran or dioxolane ring, R1 represents hydroxy, carboxy, alkoxycarbonyl, etc., R2s may be the same or different from each other and each represents hydrogen, alkyl, etc., R?3 and R4¿ may be the same or different from each other and each represents hydrogen, halogen, alkyl, amino, alkoxy, etc., R?5, R6, R7 and R8¿ may be the same or different from one another and each represents hydrogen or alkyl, m represents an integer of 0 to 3, and symbol ...... means that there may be a double bond formed by R?6 and R8¿. The compound (1) has a positively inotropic effect on myocardia and an antiarrhythmic effect and can dilate blood vessels without extremely increasing the heart rate. Therefore, a remedy for cardiac diseases containing the same as the active ingredient is remarkably useful for treating cardiac insufficiency, arrhythmia, and so forth.

Abstract translation: 由通式所表示的喹啉衍生物（1），其药物上可接受的盐，以及用于心脏病含有相同，worin环A darstellt呋喃，二氢呋喃或二氧戊环的补救，R <1> darstellt羟基，羧基，烷氧基羰基， 等，R <2> S可以是相同的或彼此和各darstellt氢，烷基等不同，R <3>和R <4>可以是从彼此，并且每个darstellt氢相同或不同， 卤素，烷基，氨基，烷氧基等，R <5> - [R <6> - [R <7>和R <8>可以相同或彼此不同，分别darstellt氢或烷基，米darstellt成整数 0至3，和符号...... bedeutet，DASS可能存在由R形成双键<6>和R <8>。 的化合物（1）对心肌和抗心律失常效果率的带正性肌力作用和可扩张血管，而不极端地增加的心脏。 因此，对于心脏病含有相同的活性成分的补救可用于治疗心功能不全，心律失常，等等非常有用。

公开(公告)号：JPH072775A

公开(公告)日：1995-01-06

申请号：JP2922791

申请日：1991-01-31

Applicant: KOWA CO

Inventor： SHIGYO HIROMICHI ,  SHIMIZU NOBORU ,  KITAMURA TAKAHIRO ,  WATANABE KOICHIRO ,  YAMAGUCHI TAKASHI ,  OTA TOMIO

IPC: B01J27/122 ,  B01J31/24 ,  C07B61/00 ,  C07D213/30

Abstract: PURPOSE:To produce a substituted phenylpyridine in a short process. CONSTITUTION:A halopyridine is reacted with 4-bromo-3-nitrophenetole in the presence of copper by using tetrakis(triphenylphosphine)palladium or palladium chloride catalyst in DMF or DMSO.

公开(公告)号：JPH05339271A

公开(公告)日：1993-12-21

申请号：JP14554592

申请日：1992-06-05

Applicant: KOWA CO

Inventor： KYOTANI YOSHINORI ,  TAIMA TSUTOMU ,  KURIHARA YUJI ,  KITAMURA TAKAHIRO ,  KAMIYA KAZUHIRO ,  YAMAGUCHI TAKASHI ,  ONOKI KAZUHIRO ,  SATO SEIICHI ,  OTA TOMIO ,  UCHIDA YASUYOSHI

IPC: A61K31/47 ,  A61K31/4741 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  C07D491/048 ,  C07D491/052

Abstract: PURPOSE:To obtain a new compound useful as a therapeutic agent for heart diseases, having anti-arrhythmic action, cardiac action and vasodilating action. CONSTITUTION:A compound of formula [A is 0 or single bond; when A is 0, B is single bond or methylene and when S is single bond, B is 0; R and R are H or lower alkyl; R is (substituted) lower alkyl, lower alkanoyloxy, hydroxyl group, etc.; broken line may contain double bond] such as 2- hydroxymethyl-9-methyl-2,3,1,8-tetrahydrofuro[3,2-g]quinolin-7-one. The compound of formula I, for example, is obtained by reacting a compound of formula II (R is lower alkanoyl) with an alkali halide such as sodium iodide.

公开(公告)号：JPH032144A

公开(公告)日：1991-01-08

申请号：JP13665289

申请日：1989-05-30

Applicant: KOWA CO

Inventor： SATO SEIICHI ,  KAWAMURA KIYOSHI ,  TAKAHASHI YOSHIO ,  WATANABE KOICHIRO ,  SHIMIZU SADAHIRO ,  OTA TOMIO

IPC: A61K31/135 ,  A61K31/165 ,  A61K31/18 ,  A61K31/195 ,  A61K31/22 ,  A61K31/24 ,  A61K31/245 ,  A61K31/25 ,  A61K31/255 ,  A61K31/27 ,  A61K31/4164 ,  A61K31/495 ,  A61K31/55 ,  A61K31/551 ,  A61P25/28 ,  C07C211/09 ,  C07C211/27 ,  C07C211/28 ,  C07C211/29 ,  C07C211/49 ,  C07C235/50 ,  C07C237/04 ,  C07C271/28 ,  C07C275/28 ,  C07C275/34 ,  C07C309/65 ,  C07C311/18 ,  C07C311/29 ,  C07C311/41 ,  C07C327/26 ,  C07C327/28 ,  C07C327/30 ,  C07C327/32 ,  C07C327/34 ,  C07C327/36 ,  C07D243/08 ,  C07D295/04 ,  C07D295/06 ,  C07D295/08 ,  C07D295/12 ,  C07D295/13 ,  C07D295/14

Abstract: NEW MATERIAL:A compound of formula I [R1-R6 are each H, halogen, OH, lower alkyl, lower alkoxy, amino, etc.; R7 and R8 are either each lower alkyl or form 1-4C alkylene through mutual linkage; A and A' are each single bond, -O-, -NH-, -NHCO-, SO2NH-, etc., (- is bond to either to Y or Y'); Y and Y' are each lower alkylene or lower alkenylene] or its acid-added salt. EXAMPLE:N,N'-bis-[4-(3,4,5-trimethoxyphenyl)buthyl]homopiperazine dihydrochloride. USE:Medicines. An active ingredient for brain protectives. Having excellent brain protective effect, low toxic, highly safe and giving great efficacy through oral administration, thus useful for the improvement or promotion inhibition of e.g. brain dysfunction involved in cerebral hemorrhage, subarachnoid hemorrhage, etc. PREPARATION:For example, a compound of formula II (X is halogen, methyloxy, etc.) is reacted with a second compound of formula III to obtain the objective compound of the formula I where Y'=Y and A'=A.